Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Novartis Pharma AG Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with…
Novartis reports final data of ALIGN trial in IgAN
Novartis has announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function…